NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: NanoViricides' NV-387 Broad-Spectrum Antiviral Development and Quarterly Report
TL;DR
NanoViricides' NV-387 offers a competitive advantage by resisting viral escape, potentially dominating antiviral markets as current vaccines lose effectiveness against evolving strains.
NV-387 works by mimicking conserved sulfated proteoglycan receptors used by over 90% of viruses, creating a broad-spectrum antiviral that prevents viral resistance mechanisms.
This technology could significantly improve global health by providing effective treatments for multiple viral diseases where current options fail vulnerable populations.
NanoViricides is developing a first-in-class antiviral that mimics human cell receptors to trap over 90% of viruses in a clever biological deception strategy.
Found this article helpful?
Share it with your network and spread the knowledge!
NanoViricides, Inc. is a publicly traded clinical stage company (NYSE American: NNVC) that creates special purpose nanomaterials for antiviral therapy, developing novel nanoviricide drug candidates based on technology licensed from TheraCour Pharma, Inc.
NV-387 is a first-in-class broad-spectrum antiviral drug candidate designed to resist viral escape by mimicking conserved sulfated proteoglycan receptors used by more than 90% of viruses, providing a mechanism that doesn't lose effectiveness as viruses evolve.
NV-387 addresses major unmet needs across multiple viral diseases including Influenza strains prone to rapid resistance, RSV, Measles, MPox, and gaps in existing Smallpox countermeasures, with current relevance given concerns about dominant A/H3N2 clade K variant and mismatched seasonal vaccines.
The Company is currently focused on advancing NV-387 into Phase II human clinical trials and plans to develop it as a treatment for RSV, COVID, Long COVID, Influenza, other respiratory viral infections, and MPOX/Smallpox infections.
Beyond NV-387, NanoViricides has NV-HHV-1 for the treatment of Shingles and is developing drugs against oral and genital Herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, HIV, Hepatitis C, Rabies, Dengue fever, Ebola virus, and others.
The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, with broad, exclusive, sub-licensable field licenses to drugs developed in several licensed fields.
NanoViricides has a Memorandum of Understanding with TheraCour for developing drugs based on TheraCour's nanomedicine technology for all antiviral infections, excluding cancer and similar diseases requiring different treatments.
The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on external collaborators and consultants, though they are currently focused on advancing NV-387 into Phase II trials.
NanoViricides holds worldwide exclusive perpetual licenses for HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza, Asian Bird Flu, Dengue, Japanese Encephalitis, West Nile, Ebola/Marburg viruses, and certain Coronaviruses.
More information is available at the company website (www.nanoviricides.com) and the full press release can be viewed at https://ibn.fm/HB3OK.
Curated from InvestorBrandNetwork (IBN)
